ATE549015T1 - Pharmazeutische wirkstoffhaltige formulierung mit überzug - Google Patents

Pharmazeutische wirkstoffhaltige formulierung mit überzug

Info

Publication number
ATE549015T1
ATE549015T1 AT04790997T AT04790997T ATE549015T1 AT E549015 T1 ATE549015 T1 AT E549015T1 AT 04790997 T AT04790997 T AT 04790997T AT 04790997 T AT04790997 T AT 04790997T AT E549015 T1 ATE549015 T1 AT E549015T1
Authority
AT
Austria
Prior art keywords
coating
active ingredients
pharmaceutical formulation
formulation containing
containing active
Prior art date
Application number
AT04790997T
Other languages
German (de)
English (en)
Inventor
Karin Klokkers
Marion Zellner
Thomas Rillmann
Andreas Dauer
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34553325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549015(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2003151301 external-priority patent/DE10351301A1/de
Priority claimed from DE200410014828 external-priority patent/DE102004014828A1/de
Application filed by Hexal Ag filed Critical Hexal Ag
Application granted granted Critical
Publication of ATE549015T1 publication Critical patent/ATE549015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04790997T 2003-10-31 2004-10-28 Pharmazeutische wirkstoffhaltige formulierung mit überzug ATE549015T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2003151301 DE10351301A1 (de) 2003-10-31 2003-10-31 Retardierte Dosisform aus mehreren Einzeleinheiten
DE200410014828 DE102004014828A1 (de) 2004-03-24 2004-03-24 Pharmazeutische wirkstoffhaltige Formulierung mit Überzug
PCT/EP2004/012230 WO2005041934A2 (de) 2003-10-31 2004-10-28 Pharmazeutische wirkstoffhaltige formulierung mit überzug

Publications (1)

Publication Number Publication Date
ATE549015T1 true ATE549015T1 (de) 2012-03-15

Family

ID=34553325

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04790997T ATE549015T1 (de) 2003-10-31 2004-10-28 Pharmazeutische wirkstoffhaltige formulierung mit überzug

Country Status (12)

Country Link
US (1) US20080254112A1 (cg-RX-API-DMAC7.html)
EP (1) EP1677766B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509891A (cg-RX-API-DMAC7.html)
AT (1) ATE549015T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004285284B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415557A (cg-RX-API-DMAC7.html)
CA (1) CA2543689A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004700A (cg-RX-API-DMAC7.html)
NO (1) NO20062051L (cg-RX-API-DMAC7.html)
NZ (1) NZ547284A (cg-RX-API-DMAC7.html)
RU (1) RU2372893C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005041934A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
MX2008010877A (es) * 2006-02-24 2008-11-25 Teva Pharma Tabletas de liberacion prolongada de succinato de metroprolol y metodos para su preparacion.
MX2009002993A (es) * 2006-09-26 2009-04-01 Novartis Ag Composiciones farmaceuticas que comprenden un modulador de s1p.
US8367115B2 (en) 2007-08-27 2013-02-05 Asahi Kasei Chemicals Corporation Process for production of crystalline cellulose and tablets containing granules
SI2187875T1 (sl) * 2007-09-21 2012-12-31 Evonik Rohm Gmbh Od pH odvisen farmacevtski sestavek z nadzorovanim sproščanjem za ne-opioide z odpornostjo na vpliv etanola
US9700520B2 (en) * 2007-09-21 2017-07-11 Evonik Roehm Gmbh PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
CA2711475A1 (en) * 2008-01-10 2009-07-16 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
HUE043474T2 (hu) 2008-01-10 2019-08-28 Evonik Roehm Gmbh Bevont gyógyszerészeti vagy gyógyhatású étrend-kiegészítõ készítmény javított pulzáló hatóanyag-felszabadulással
RU2011102777A (ru) * 2008-06-26 2012-08-10 МакНЕЙЛ-ППС, ИНК. (US) Частицы с покрытием, содержащие фармацевтически активные агенты
JPWO2010026993A1 (ja) 2008-09-03 2012-02-02 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
PL2408436T3 (pl) * 2009-03-18 2017-08-31 Evonik Röhm Gmbh Kompozycja farmaceutyczna o kontrolowanym uwalnianiu z odpornością na wpływ etanolu, wykorzystująca powłokę zawierającą neutralne polimery winylowe i zaróbki
US20110311631A1 (en) * 2009-03-18 2011-12-22 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
WO2010132204A1 (en) 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
WO2010132205A1 (en) * 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Film coatings containing fine particle size detackifiers and substrates coated therewith
PH12012502153A1 (en) 2010-04-30 2013-02-04 Takeda Pharmaceuticals Co Enteric tablet
CA2797809A1 (en) 2010-04-30 2011-11-03 Takeda Pharmaceutical Company Limited Enteric tablet
FR2968559B1 (fr) * 2010-12-14 2012-12-28 Alexandra Fregonese Nouvelles compositions a base d'argile et de beepollen, leur procede de preparation et leurs utilisations en nutrition et en therapeutique
JP6110384B2 (ja) * 2011-09-16 2017-04-05 パーデュー ファーマ エルピー 不正改変抵抗性医薬製剤
AU2012310251B2 (en) * 2011-09-16 2016-01-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2021030550A1 (en) 2019-08-13 2021-02-18 Mccord Darlene E NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS
JP7482645B2 (ja) * 2020-02-18 2024-05-14 沢井製薬株式会社 核粒子を含む顆粒の製造方法
WO2023076855A1 (en) 2021-10-25 2023-05-04 Mccord Darlene E Coated medicinal clay compositions, pharmaceutical compositions, and delivery of cation sources and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110814A (en) * 1989-01-11 1992-05-05 Asta Pharma Ag Azelastine and its salts used to combat psoriasis
DE3900811A1 (de) * 1989-01-13 1990-07-19 Kali Chemie Pharma Gmbh Neue arzneiform
CH687810A5 (de) * 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
CA2177769C (en) * 1995-06-07 1999-08-24 Gyanesh P. Khare Particulate compositions that comprise zinc aluminate
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6599529B1 (en) * 1997-09-11 2003-07-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
DE19905906A1 (de) * 1999-02-11 2000-08-17 Basf Ag Verwendung von wasserlöslichen oder wasserdispergierbaren Polyether-haltigen Polymerisaten als Überzugsmittel, Bindemittel und/oder filmbildender Hilfsstoff in pharmazeutischen Darreichungsformen
DE19850238A1 (de) * 1998-10-31 2000-05-04 Triple Trian Beteiligungs Gmbh Verfahren und Vorrichtung zur Kompensation von Elektrosmog
US7070803B2 (en) * 2000-03-31 2006-07-04 Nycomed Austria Gmbh Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
RU2323717C2 (ru) * 2001-12-19 2008-05-10 Астразенека Аб Новое пленочное покрытие
BRPI0413353A (pt) * 2003-08-06 2006-10-10 Nirmal Mulye composição farmacêutica contendo droga solúvel em água

Also Published As

Publication number Publication date
WO2005041934A3 (de) 2005-12-01
US20080254112A1 (en) 2008-10-16
JP2007509891A (ja) 2007-04-19
EP1677766B1 (de) 2012-03-14
NZ547284A (en) 2009-12-24
NO20062051L (no) 2006-07-25
WO2005041934A2 (de) 2005-05-12
BRPI0415557A (pt) 2006-12-26
MXPA06004700A (es) 2006-07-05
CA2543689A1 (en) 2005-05-12
AU2004285284B2 (en) 2010-03-25
RU2372893C2 (ru) 2009-11-20
EP1677766A2 (de) 2006-07-12
AU2004285284A1 (en) 2005-05-12
RU2006118689A (ru) 2007-12-20

Similar Documents

Publication Publication Date Title
ATE549015T1 (de) Pharmazeutische wirkstoffhaltige formulierung mit überzug
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
DE60126433D1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
EP1354590A4 (en) MEDICINES AGAINST JOINT DEFECTS
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
HUP0402230A2 (hu) Többszörös bevonattal ellátott gyógyszer dózisforma
NZ594618A (en) Transdermal pharmaceutical preparations
BR0211198A (pt) Composições farmacêuticas e seu uso
FI2180887T3 (fi) Farmaseuttisia preparaatioita sisältäen voimakkaasti volatiilisia silikoneja
WO2005117895A8 (en) Compositions comprising meloxicam
BR0317452A (pt) Métodos para revestimento de substratos para usos farmacêuticos com uma mistura de dois agentes de revestimento formadores de pelìculas
WO2005004915A3 (en) Compositions comprising meloxicam
DE60316714D1 (de) Pharmazeutische formulierung enthaltend olanzapin
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GEP20043377B (en) Pharmaceutical Complex
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
BR0115206A (pt) Composições hidroliticamente instáveis